Treatment group | Â | Days post-Treatmenta
|
---|
 | Day 0 | Day 28–30 | Day 54–60 | Day 82–86 |
---|
Fluralaner b
| # Dogs | 34 | 34 | 33 | 33 |
Mean PVAS Scored
| 7.3 | 1.7 | 0.9 | 0.9 |
STDEV | 2.40 | 1.8 | 1.2 | 1.3 |
Range | (2.2–10) | (0-6) | (0-4.2) | (0-4.2) |
Reductione
| Â | 77.0 % | 87.5 % | 88.0 % |
Afoxolaner c
| # Dogs | 27 | 27 | 26 | 23 |
Mean PVAS Scored
| 7.1 | 1.5 | 0.7 | 0.7 |
STDEV | 2.2 | 1.8 | 0.9 | 1.4 |
Range | (2.7–10) | (0-6.5) | (0-3.6) | (0-6.7) |
Reduction | Â | 79.2Â % | 89.6Â % | 89.7Â % |
-
aIn both groups dogs were treated on day 0. In the afoxolaner group dogs were also treated once between days 28–30 and once between days 54–60
-
bDogs were orally administered fluralaner chews (Bravecto® Merck Animal Health) according to label directions
-
cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.) according to label directions
-
dArithmetic mean pruritus score as assessed by dog owners using the PVAS (Hill et al. Vet Dermatol 18(5):301–308, 2004)
-
e{(Day 0 arithmetic mean FAD score—day x arithmetic mean FAD score)/day 0 arithmetic mean FAD score)} x 100